Navigation Links
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
Date:5/1/2009

BONITA SPRINGS, Fla., May 1 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that dosing has started in a Phase I clinical trial of GGTI-2418. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

The Phase I study is led by Dr. Peter O'Dwyer, Professor of Medicine at the University of Pennsylvania School of Medicine and Program Leader of the Experimental Therapeutics Program at the Abramson Cancer Center of the University of Pennsylvania, and by Dr. Gabriela Chiorean, Assistant Professor of Medicine at the Indiana University School of Medicine and a physician/researcher with the Indiana University Melvin and Bren Simon Cancer Center.

"This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "Initiation of this Phase I study of GGTI-2418 in these two top Phase I cancer research centers is a significant step in the development of this first-in-class molecule to treat cancer in many different tumor types."

"We are excited to participate in the first study of this novel agent," commented Dr. Chiorean. "The development of a molecule to inhibit the geranylgeranyltransferase pathway would be a significant advancement in cancer treatment."

The primary objective of the Company's Phase I trial with GGTI-2418 is to determine its safety, tolerability, and recommended Phase II dose. Patients with metastatic solid tumors for which standard treatments have failed, or for whom standard therapies are not available, will be evaluated. The number of patients to be enrolled will depend on the number of patient cohorts investigated until dose-limiting toxicity
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015   ... für Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für ... Royal Philips (NYSE: PHG, AEX: PHIA) ... 2015 (ECR) bekannt, der vom 4. bis 8. März ... den Ständen Nr. 102 and 110 ...
(Date:3/3/2015)... 3, 2015 NASA astronaut Scott Kelly , ... to spend a year living and working on the International ... 5:30 to 7 a.m. EDT Monday, March 9. ... he completes the final weeks of his training. The interviews ... NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has ... 2015 - 2025" report to their offering. ... an extensive study on the marketed and pipeline gene ... in this field for over a decade but there ... markets; one approved in the EU). There are many ...
(Date:3/3/2015)... -- Adaptive Biotechnologies announced today that Chad Cohen ... Director as Chair of the Audit Committee. ... all finance, treasury and accounting functions. Since joining Zillow ... and accounting functions, and led the finance organization through ... was named Puget Sound Business Journal,s CFO of the ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... ROCKVILLE, Md., Sept. 2 Human Genome,Sciences, Inc. ... presentation at the,2008 Thomas Weisel Partners Annual Healthcare ... http://www.hgsi.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ... senior management team will present,a corporate overview on ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical ... therapies, announced today that,Anthony DiTonno, President and Chief ... Stanley Global Healthcare Unplugged Conference in New,York City ... Stephen Ghiglieri,Chief Financial Officer, will be available to ...
... patents; Purdue licenses ... oxycodone strengths, STAMFORD, Conn., Sept. 2 Purdue ... Missouri have,agreed to end the OxyContin(R) (oxycodone HCl controlled-release) ... District,Court for the Southern District of New York., ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Application: The greater incorporation of Br-dUTP results ... when detected using a fluorescein-labeled anti-BrdU antibody. ... in the kit to counterstain the total ... Br-dUTP, resulting in improved detection than found ...
... For transient, cytoplasmic expression of an ... of interest or selection marker from bicistronic ... into MCS1 and MCS2 for transcription of ... This vector is useful for protein-protein interaction ...
...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Biology Products: